Genmab A/S
GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.60−0.75 (-1.46%)
Close on Nov 20, 2026
Genmab A/S J&J / Janssen Collaboration & Royalty Revenue by Quarter
J&J / Janssen Collaboration & Royalty Revenue ($M)
Genmab A/S J&J / Janssen Collaboration & Royalty Revenue: $794M in Q3 2026, up 14.4% from a year earlier. That is the highest of the 11 quarters on record here.
Latest, Q3 2026
794
Period ended Sep 30, 2026
Change on a year earlier
+14.4%
694 in Q3 2025
History
11 quarters
Since Q1 2024
Sources
7
Documents cited below
Where the Q3 2026 figure comes from
“|| J&J | $ | 794 | $ | 694 | $ | 2,169 | $ | 1,831”
Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Genmab A/S J&J / Janssen Collaboration & Royalty Revenue ($M), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/partner-jnj
See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.
See a number that looks wrong?